Greenroc Strategic Materials (LON: GROC) has secured a €5.2m secured loan facility to finance work at the Amitsoq graphite mine in south Greenland and the establishment of a European pilot plant to produce active anode material. The loan can be drawn down over the first two years and has a maturity of five year. The lender can choose to take shares at a 20% discount to the market price when the loan matures. The share price increased 14.6% to 2.75p.
An interim trading update from market research services provider System1 Group (LON: SYS1) says interim revenues were 7% lower at £17.1m, but it is winning new clients. Existing clients are being retained but they are spending less. The share price recovered 11.1% to 240p.
Molecular diagnostics company Novacyt (LON: NCYT) expects second half revenues to be slightly higher than those in the first half and the full year loss will be lower than in 2024. The long-term strategy is to generate double digit annual growth in revenues and keep gross margin above 60%. New product launches will help. The share price rose 10.9% to 43.15p.
Advanced coatings provider Hardide (LON: HDD) had a strong fourth quarter that enabled its to move into profit. In the year to September 2025, revenues rose by around one-quarter to £6m, which is higher than forecast. Aerospace revenues are building up. Cavendish expects the pre-tax profit to improve from £100,000 this year to £700,000 this year. There is spare capacity to grow into. The share price is 8.11% higher at 8p.
Shares in Trellus Health (LON: TRLS) rebounded 7.69% to 0.7p after it signed a contract with a leading global contract research organisation (CRO), although it will not immediately extend the company’s cash beyond December. This was mentioned in yesterday’s trading statement. The 12 month contract will support recruitment and enrolment for an ongoing clinical trial in immunology and inflammation. The contract will start later this year. Trellus Health has also been granted preferred vendor status with another CRO. Additional funding is still required.
Wines retailer Virgin Wines (LON: VINO) reported full year figures in line with expectations and the increased spending on marketing is showing signs of paying off. Revenues were flat at £59m and the pe-tax profit declined from £1.7m to £1.6m. However, customer retention is improving and there was a 29% increase in customer acquisition in the first quarter as the marketing spending starts to pay off. Commercial and Warehouse Wines sales are growing strongly. The additional investment in growing the business means that Virgin Wines will fall into loss on higher revenues this year before returning to profit next year. The share price improved 5.53% to 51.5p.
FALLERS
Lung imaging technology developer Polarean Imaging (LON: POLX) is undertaking a strategic review of the business. This includes whether to stay on AIM, where liquidity has been poor. The cost base is also being assessed. Leaving AIM could help to reduce costs and could make it easier to generate additional funding. The share price dived 46.3% to 0.215p.
Oxford BioDynamics (LON: OBD) is raising £7m at 0.3p/share. The clinical diagnostics company will use the cash for working capital as test sales build up and it seeks licencing and distribution agreements. The share price fell 37% to 0.315p.
Shares in Trafalgar Property Group (LON: TRAF) returned from suspension down 14.3% to 0.015p after it published accounts for the year to March 2025.